Clinical Trial: Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07733349) titled 'Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease' on July 23.

Brief Summary: This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.

Study Start Date: Aug. 03

Study Type: INTERVENTIONAL

Condition: Parkinson's Disease

Intervention: DRUG: UX-DA003

UX-DA003 (Human Allogeneic iPSC-derived Midbrain Dopaminergic Progenitor cells) is used for treating patients with PD via implanting into bilateral putamina under stereotactic neurosurgery.

Recruitment...